By Leukemia & Lymphoma Society
Light The Night Walks not only bring attention to the need to find cures for blood cancer but they also show the importance of The Leukemia & Lymphoma Society’s (LLS) corporate partners when it comes to advancing breakthrough therapies.
Celgene is LLS’s number one Light The Night National Pharmaceutical Partner – raising more than $1 million since becoming a National Sponsor in 2010.
The company returned once again this year to rally employees to participate in community walks. Celgene currently has 94 teams and more than 1,400 registered walkers and $275,000 raised to date. Team Celgene anticipated they will surpass their collective goal of $300,000, which will go to LLS to help fund research for new treatments for blood cancer patients.
The recipe for that success was cooperation by Celgene’s senior leadership team, national team captains and the many local team captains across the country.
“The support of dedicated partners like Celgene and its employees has been key in LLS’s commitment to funding research to find cures and life-saving therapies for blood cancer patients and make sure patients have access to the treatments they need,” said president and CEO Louis J. DeGennaro, who joined the Boston team for the October 9 walk. “It’s particularly rewarding to see a biopharmaceutical firm literally take to the streets and walk alongside the patients they are working to help.”
It’s particularly rewarding to see a biopharmaceutical firm literally take to the streets and walk alongside the patients they are working to help.
Last year, Celgene was recognized as LLS’s top national pharmaceutical partner and its fifth largest national partner overall.
“Celgene employees have been able to see how the company’s support of LLS’s patient programs and research has had a direct impact on patients. The enthusiasm has been contagious and the entire organization has united as corporate volunteers to support the LLS mission,” said Adam Waldman, Celgene’s executive director and head of U.S. hematology marketing.
Corporate support has helped LLS continue major advances toward cures for blood cancer. Since 1949, LLS has invested more than $1 billion, supporting some of the best researchers in the world and helping to achieve dramatic increases in the survival rates for both childhood and adult leukemias.
Celgene also supports the LLS’s Quest for Cures grants program, which identifies and funds priority research areas with the help of biotechnology and pharmaceutical partners.